Compare OCSL & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | VOR |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2007 | 2021 |
| Metric | OCSL | VOR |
|---|---|---|
| Price | $11.68 | $19.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $12.63 | ★ $45.33 |
| AVG Volume (30 Days) | 462.8K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $1.62 |
| 52 Week High | $14.49 | $49.95 |
| Indicator | OCSL | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 56.67 |
| Support Level | $11.01 | $11.62 |
| Resistance Level | $12.35 | $19.70 |
| Average True Range (ATR) | 0.23 | 1.49 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 13.90 | 55.84 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.